Development of morphine glucuronidation in premature neonates

Area of Science:

• Pharmacology
• Neonatal Medicine
• Drug Metabolism

Background:

• Premature neonates exhibit altered drug metabolism compared to full-term infants.
• Morphine is commonly used for pain management in neonatal intensive care units.
• Understanding morphine pharmacokinetics is crucial for safe and effective pain control in vulnerable neonates.

Purpose of the Study:

• To investigate the pharmacokinetic profile of morphine and its metabolites in premature neonates.
• To assess the impact of gestational age and birth weight on morphine metabolism.
• To explore the in vivo development of specific drug-metabolizing enzymes in human neonates.

Main Methods:

• Intravenous administration of morphine to premature neonates (25-34 weeks gestation) within the first 24 hours of life.
• Plasma sampling after a 2-hour loading infusion and a 24-hour continuous infusion.
• Quantification of morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) using validated analytical techniques.

Main Results:

• Morphine and M3G were detected after a 2-hour infusion; M6G was quantifiable after 24 hours.
• M3G/morphine and M6G/morphine plasma concentration ratios increased with birth weight.
• The M6G/M3G ratio decreased with increasing birth weight and gestational age.

Conclusions:

• Neonatal morphine metabolism changes significantly within the first 24 hours of life.
• The observed changes in metabolite ratios suggest differential development of uridinediphosphate glucuronosyltransferases (UGTs) in premature neonates.
• This study provides the first in vivo evidence of differential UGT development in humans, influenced by birth weight and gestational age.